Loading...
Norfloxacin therapy has been investigated for its potential to prevent spontaneous bacterial peritonitis (SBP) and improve survival in patients with advanced cirrhosis, but results of several small studies are conflicting.
To examine this issue further, researchers conducted a double-blind, placebo-controlled study among approximately 300 patients with Child-Pugh class C cirrhosis who had not received fluoroquinolones within the past month. The primary outcome was 6-month mortality, and the secondary outcome was infection prevention.
Patients were randomized to receive daily norfloxacin 400 mg or placebo for 6 months. Baseline characteristics were similar between groups. Over three fourths of patients had alcoholic cirrhosis, and less than 5%…